Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,926 | 282 | 98.5% |
| Education | $57.83 | 7 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $988.06 | 93 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $435.92 | 25 | $0 (2021) |
| Takeda Pharmaceuticals America, Inc. | $289.05 | 41 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $256.49 | 16 | $0 (2021) |
| GlaxoSmithKline, LLC. | $235.06 | 13 | $0 (2023) |
| ABBVIE INC. | $206.73 | 9 | $0 (2024) |
| PFIZER INC. | $181.67 | 11 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $164.28 | 11 | $0 (2021) |
| Allergan, Inc. | $143.25 | 9 | $0 (2020) |
| Amgen Inc. | $121.30 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $146.36 | 6 | ABBVIE INC. ($106.92) |
| 2023 | $20.45 | 1 | GlaxoSmithKline, LLC. ($20.45) |
| 2022 | $37.10 | 2 | Novartis Pharmaceuticals Corporation ($21.90) |
| 2021 | $662.42 | 36 | AbbVie Inc. ($84.61) |
| 2020 | $508.47 | 30 | AstraZeneca Pharmaceuticals LP ($113.64) |
| 2019 | $608.74 | 47 | Takeda Pharmaceuticals U.S.A., Inc. ($169.06) |
| 2018 | $1,271 | 102 | Takeda Pharmaceuticals U.S.A., Inc. ($742.61) |
| 2017 | $729.06 | 65 | Takeda Pharmaceuticals America, Inc. ($289.05) |
All Payment Transactions
289 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: NEUROSCIENCE | ||||||
| 06/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Cardio-renal | ||||||
| 02/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: NEUROSCIENCE | ||||||
| 02/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.30 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: RESPIRATORY | ||||||
| 04/12/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: NEUROSCIENCE | ||||||
| 01/04/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: NEUROSCIENCE | ||||||
| 10/19/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: RESPIRATORY | ||||||
| 09/28/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: NEUROSCIENCE | ||||||
| 09/07/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: RESPIRATORY | ||||||
| 08/19/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: NEUROSCIENCE | ||||||
| 08/12/2021 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 07/29/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: DIABETES | ||||||
| 07/08/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: PRIMARY CARE | ||||||
| 06/24/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: RESPIRATORY | ||||||
| 06/15/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2021 | Merck Sharp & Dohme Corporation | BELSOMRA (Drug), JANUVIA, STEGLATRO | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2021 | ORGANOGENESIS INC. | Puraply Antimicrobial (Medical Supply) | Food and Beverage | Cash or cash equivalent | $23.51 | General |
| Category: Wound Care | ||||||
| 05/25/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Bone Health | ||||||
| 05/20/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: DIABETES | ||||||
| 05/11/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 14 | 1,175 | 1,575 | $387,247 | $121,103 |
| 2020 | 21 | 1,395 | 1,760 | $405,465 | $127,947 |
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 356 | 555 | $171,897 | $47,271 | 27.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 208 | 208 | $62,192 | $28,658 | 46.1% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 220 | 220 | $48,620 | $11,562 | 23.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 97 | 104 | $22,607 | $6,065 | 26.8% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2021 | 45 | 45 | $5,850 | $5,612 | 95.9% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 23 | 24 | $13,248 | $5,563 | 42.0% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 28 | 28 | $11,844 | $4,881 | 41.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 47 | $19,839 | $4,594 | 23.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $13,472 | $3,882 | 28.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 27 | 89 | $4,005 | $928.25 | 23.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 52 | 52 | $3,380 | $908.97 | 26.9% |
| 17000 | Destruction of skin growth | Office | 2021 | 14 | 16 | $2,752 | $798.87 | 29.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 15 | 15 | $960.00 | $261.66 | 27.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 17 | 140 | $6,580 | $117.79 | 1.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 311 | 487 | $134,899 | $35,332 | 26.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 203 | 203 | $61,285 | $24,152 | 39.4% |
| 99497 | Advance care planning by the physician or other qualified health care professional | Office | 2020 | 280 | 280 | $61,448 | $20,279 | 33.0% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2020 | 73 | 73 | $32,059 | $12,809 | 40.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 183 | 196 | $36,848 | $8,397 | 22.8% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2020 | 27 | 36 | $21,376 | $7,039 | 32.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 29 | 43 | $16,039 | $4,828 | 30.1% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2020 | 14 | 14 | $4,200 | $3,044 | 72.5% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2020 | 22 | 22 | $2,925 | $2,574 | 88.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 22 | 22 | $9,338 | $2,102 | 22.5% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2020 | 12 | 12 | $5,084 | $2,052 | 40.4% |
About Dr. John Holman, MD
Dr. John Holman, MD is a Family Medicine healthcare provider based in Minden, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1215938394.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Holman, MD has received a total of $3,984 in payments from pharmaceutical and medical device companies, with $146.36 received in 2024. These payments were reported across 289 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($3,926).
As a Medicare-enrolled provider, Holman has provided services to 2,570 Medicare beneficiaries, totaling 3,335 services with total Medicare billing of $249,050. Data is available for 2 years (2020–2021), covering 35 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Minden, NV
- Active Since 08/10/2005
- Last Updated 09/18/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1215938394
Products in Payments
- Trintellix (Drug) $718.36
- Amitiza (Drug) $266.13
- JARDIANCE (Drug) $255.73
- VRAYLAR (Drug) $213.44
- TRELEGY ELLIPTA (Drug) $129.87
- Uloric (Drug) $125.84
- JANUVIA (Drug) $105.06
- SYMBICORT (Drug) $104.40
- FARXIGA (Drug) $101.91
- SPIRIVA RESPIMAT (Drug) $90.60
- ClosureFast (Device) $79.46
- ENTRESTO (Drug) $77.57
- TRINTELLIX (Drug) $76.39
- ELIQUIS (Drug) $66.21
- Victoza (Drug) $63.80
- Prolia (Biological) $61.05
- Dexilant (Drug) $56.24
- PREVNAR 13 (Biological) $52.27
- SOLIQUA 100/33 (Biological) $50.35
- Puraply Antimicrobial (Medical Supply) $48.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Minden
Joseph Nida, M.d, M.D
Family Medicine — Payments: $7,100
Dr. Christopher Earnhardt, Md, MD
Family Medicine — Payments: $5,874
Dr. Dustin Riley, Md, MD
Family Medicine — Payments: $4,815
Dr. Douglas Althouse, Md, MD
Family Medicine — Payments: $2,343
Dr. David Hoskins, Md, MD
Family Medicine — Payments: $2,192
Dr. John Craig, M.d, M.D
Family Medicine — Payments: $2,040